KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Other Accumulated Expenses (2016 - 2026)

Gsk has reported Other Accumulated Expenses over the past 18 years, most recently at -$780.6 million for Q1 2026.

  • For Q1 2026, Other Accumulated Expenses fell 11.67% year-over-year to -$780.6 million; the TTM value through Mar 2026 reached -$780.6 million, down 11.67%, while the annual FY2025 figure was -$811.4 million, 7.33% down from the prior year.
  • Other Accumulated Expenses for Q1 2026 was -$780.6 million at Gsk, up from -$811.4 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at -$40.3 million in Q1 2022 and troughed at -$908.1 million in Q3 2025.
  • A 5-year average of -$670.0 million and a median of -$691.6 million in 2023 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: soared 95.66% in 2022 and later plummeted 1521.48% in 2023.
  • Year by year, Other Accumulated Expenses stood at -$624.0 million in 2022, then increased by 1.54% to -$614.4 million in 2023, then dropped by 23.05% to -$756.0 million in 2024, then decreased by 7.33% to -$811.4 million in 2025, then increased by 3.8% to -$780.6 million in 2026.
  • Business Quant data shows Other Accumulated Expenses for GSK at -$780.6 million in Q1 2026, -$811.4 million in Q4 2025, and -$908.1 million in Q3 2025.